ישראל - עברית - Ministry of Health

bayer israel ltd - interferon beta 1b - אבקה וממס להכנת תמיסה להזרקה - interferon beta 1b 0.3 mg/vial - interferon beta-1b - interferon beta-1b - use in ambulatory patients with relapsing-remitting multiple sclerosis (rrms) and relapsing progressive m.s. to reduce the frequency of clinical exacerbations. treatment of secondary progressive (sp) form of multiple sclerosis. treatment of patients who have experienced a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, including the prescence of mri abnormalities characteristic of m.s. and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

ישראל - עברית - Ministry of Health

teva israel ltd - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/ml - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/dose - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.

ישראל - עברית - Ministry of Health

טבע מדיקל (שיווק) בע"מ - אחות - the colleague pump is designed to deliver infusion therapies via clinically acceptable routes of administration, including intravenous, intra-arterial, epidural, and subcutaneous routes.

ישראל - עברית - Ministry of Health

uc-care ltd. - רופא - the uc-care navigotm workstation is intended to be used by physicians in the clinic or hospital for 2-d and 3-d visualization of ultrasound images of the prostate gland. additional software features assist biopsy procedures include patient data management, multi-planar reconstruction, segmentation, image measurement and 3-d image registration. the device is specifically indicated for reconstruction of a 3d rendered surface model of the prostate and to display locations for biopsies that have been selected by the physician, as well as storage and future retrieval of this information. the expected system accuracy is ±5 mm. this includes the accuracy of the prostate surface that is presented to the practitioner over the navigotm workstation screen during 3d model reconstructions and also the accuracy of the biopsy needle trajectory that is presented to the practitioner over the navigotm workstation screen during the biopsy session. all clinical decisions taken regarding the use of the uc-care navigo™ workstation

ישראל - עברית - Ministry of Health

merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - קפסולה קשיחה - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob